We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

New Treatments for Non-Hodgkin's Lymphoma

By HospiMedica staff writers
Posted on 20 Dec 2000
Interim results from a study has found that a cloned antibody (Rituxan) combined with conventional chemotherapy resulted in a one-year survival rate of 83% in patients with non-Hodgkin's lymphoma (NHL), compared to 68% for a standard combination of chemotherapy and drugs. More...
Overall, 69% of patients treated with the combination therapy were shown to be free of the disease, compared to only 49% treated with chemotherapy alone. The study was conducted in Lyon, France. Rituxan is comarketed by Genentech (So. San Francisco, CA, USA) and Idec Pharmaceuticals (USA).

Another study involved patients with low-grade and transformed low-grade NHL who failed to respond to or progressed following treatment with retuximab. Treatment with this monoclonal antibody conjugated with a radioisotope (tositumomab, iodine I 131 tositumomab) called Bexxar produced a 70% overall response rate and a 40% complete response rate in these patients. Longer-term data showed a 35% complete response rate lasting a median of more than three years. Bexxar is being comarketed by Coulter Pharmacuetical, Inc. (So. San Francisco, CA, USA) and SmithKline Beecham (London, UK).



Related Links:
Coulter Pharma
SmithKline Beecham

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Tourniquet System
heidi– mein Tourniquet
New
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.